Trials / Recruiting
RecruitingNCT03702309
Liquid Biopsy Evaluation and Repository Development at Princess Margaret
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,500 (estimated)
- Sponsor
- University Health Network, Toronto · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The objective of this protocol is to develop an institution-wide liquid biopsy protocol that will establish a common process for collecting blood and corresponding archived tumor specimens for future research studies at the University Health Network's Princess Margaret Cancer Centre. Circulating cell-free nucleic acids (cfNA), including cell-free DNA (cfDNA) and cell-free RNA (cfRNA), are non-invasive, real-time biomarkers that can provide diagnostic and prognostic information before cancer diagnosis, during cancer treatment, and at disease progression. Cancer research scientists and clinicians at the Princess Margaret are interested in incorporating the collection of peripheral blood samples ("liquid biopsies") into research protocols as a means of non-invasively assessing tumor progression and response to treatment at multiple time points during a patient's course of disease.
Conditions
- Cancer
- Breast Cancer
- Lung Cancer
- Colon Cancer
- Ovarian Cancer
- Melanoma
- Lymphoma
- Leukemia
- Mutation
- Lynch Syndrome
- Cowden Syndrome
- BRCA1 Mutation
- BRCA2 Mutation
- Uterine Cancer
- Myeloma
- Kidney Cancer
- Head and Neck Cancer
- Meningioma
Timeline
- Start date
- 2017-08-03
- Primary completion
- 2026-07-06
- Completion
- 2026-07-06
- First posted
- 2018-10-11
- Last updated
- 2025-11-26
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT03702309. Inclusion in this directory is not an endorsement.